The Active Core in a Triazole Peptide Dual‐Site Antagonist of HIV‐1 gp120
- 28 October 2010
- journal article
- research article
- Published by Wiley in ChemMedChem
- Vol. 5 (11), 1871-1879
- https://doi.org/10.1002/cmdc.201000222
Abstract
In an effort to identify broadly active inhibitors of HIV‐1 entry into host cells, we previously reported a family of dodecamer triazole–peptide conjugates with nanomolar affinity for the viral surface protein gp120. This peptide class exhibits potent antiviral activity and the capacity to simultaneously inhibit interaction of the viral envelope protein with both CD4 and co‐receptor. In this investigation, we minimized the structural complexity of the lead triazole inhibitor HNG‐156 (peptide 1 ) to explore the limits of the pharmacophore that enables dual antagonism and to improve opportunities for peptidomimetic design. Truncations of both carboxy‐ and amino‐terminal residues from the parent 12‐residue peptide 1 were found to have minimal effects on both affinity and antiviral activity. In contrast, the central triazole(Pro)‐Trp cluster at residues 6 and 7 with ferrocenyl‐triazole(Pro) (Ftp) was found to be critical for bioactivity. Amino‐terminal residues distal to the central triazole(Pro)‐Trp sequence tolerated decreasing degrees of side chain variation upon approaching the central cluster. A peptide fragment containing residues 3–7 (Asn‐Asn‐Ile‐Ftp‐Trp) exhibited substantial direct binding affinity, antiviral potency, dual receptor site antagonism, and induction of gp120 structuring, all properties that define the functional signature of the parent compound 1 . This active core contains a stereochemically specific hydrophobic triazole(Pro)‐Trp cluster, with a short N‐terminal peptide extension providing groups for potential main chain and side chain hydrogen bonding. The results of this work argue that the pharmacophore for dual antagonism is structurally limited, thereby enhancing the potential to develop minimized peptidomimetic HIV‐1 entry inhibitors that simultaneously suppress binding of envelope protein to both of its host cell receptors. The results also argue that the target epitope on gp120 is relatively small, pointing to a localized allosteric inhibition site in the HIV‐1 envelope that could be targeted for small‐molecule inhibitor discovery.Keywords
This publication has 42 references indexed in Scilit:
- Soluble CD4 and CD4-Mimetic Compounds Inhibit HIV-1 Infection by Induction of a Short-Lived Activated StatePLoS Pathogens, 2009
- Small-Molecule CD4 Mimics Interact with a Highly Conserved Pocket on HIV-1 gp120Structure, 2008
- Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strainsProceedings of the National Academy of Sciences of the United States of America, 2008
- Introducing metallocene into a triazole peptide conjugate reduces its off‐rate and enhances its affinity and antiviral potency for HIV‐1 gp120Journal of Molecular Recognition, 2008
- Structural Determinants for Affinity Enhancement of a Dual Antagonist Peptide Entry Inhibitor of Human Immunodeficiency Virus Type-1Journal of Medicinal Chemistry, 2008
- Crystal Structure and Structural Mechanism of a Novel Anti-Human Immunodeficiency Virus andd-Amino Acid-Containing ChemokineJournal of Virology, 2007
- Broad-Spectrum Anti-Human Immunodeficiency Virus (HIV) Potential of a Peptide HIV Type 1 Entry InhibitorJournal of Virology, 2007
- Thermodynamics of Binding of a Low-Molecular-Weight CD4 Mimetic to HIV-1 gp120Biochemistry, 2006
- Click Chemistry on Azidoproline: High‐Affinity Dual Antagonist for HIV‐1 Envelope Glycoprotein gp120ChemMedChem, 2006
- CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5Nature, 1996